Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy

References

• VilstrupHAmodioPBajajJHepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the LiverHepatology201460271573525042402
   PubMed Web of Science ®Google Scholar
• RiggioORidolaLPasqualeCEvidence of persistent cognitive impairment after resolution of overt hepatic encephalopathyClin Gastroenterol Hepatol20119218118320951832
   PubMed Web of Science ®Google Scholar
• PereiraKCarrionAFSalsamendiJDoshiMBakerRKablyIEndovascular Management of Refractory Hepatic Encephalopathy Complication of Transjugular Intrahepatic Portosystemic Shunt (TIPS): Comprehensive Review and Clinical Practice AlgorithmCardiovasc Intervent Radiol201639217018226285910
   PubMed Web of Science ®Google Scholar
• StepanovaMMishraAVenkatesanCYounossiZMIn-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009Clin Gastroenterol Hepatol20121091034.e11041.e122642955
   PubMed Web of Science ®Google Scholar
• AmodioPDel PiccoloFPettenòEPrevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patientsJ Hepatol2001351374511495040
   PubMed Web of Science ®Google Scholar
• CordobaJVentura-CotsMSimón-TaleroMCANONIC Study Investigators of EASL-CLIF ConsortiumCharacteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF)J Hepatol201460227528124128414
   PubMed Web of Science ®Google Scholar
• JiangQJiangXHZhengMHJiangLMChenYPWangLRifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysisEur J Gastroenterol Hepatol200820111064107019047837
   PubMed Web of Science ®Google Scholar
• ZhuGQShiKQHuangSSystematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathyAliment Pharmacol Ther201541762463525684317
   PubMed Web of Science ®Google Scholar
• GluudLLVilstrupHMorganMYNonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysisHepatology201664390892227081787
   PubMed Web of Science ®Google Scholar
• KimerNKragAMøllerSBendtsenFGluudLLSystematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathyAliment Pharmacol Ther201440212313224849268
   PubMed Web of Science ®Google Scholar
• BassNMMullenKDSanyalARifaximin treatment in hepatic encephalopathyN Engl J Med2010362121071108120335583
   PubMed Web of Science ®Google Scholar
• WuDWuSMLuJZhouYQXuLGuoCYRifaximin versus Non-absorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-AnalysisGastroenterol Res Pract2013201323696323653636
   PubMed Web of Science ®Google Scholar
• GaoZMClinical observation of rifaximin combined with lactulose for the treatment of hepatic encephalopathy[J]J China Tradit Chinese Med Inform201242381
   Google Scholar
• NeffGWFlammSLMullenKDSu1298 Improved Outcomes in Hepatic Encephalopathy Using Rifaximin Monotherapy Compared to Rifaximin and Lactulose Combination TherapyGastroenterology20131445S451
   Web of Science ®Google Scholar
• SharmaBCSharmaPLuniaMKSrivastavaSGoyalRSarinSKA randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathyAm J Gastroenterol201310891458146323877348
   PubMed Web of Science ®Google Scholar
• GillMLNiazTAzizHKhanSP440 outcomes of rifaximin plus lactulose versus lactulose alone in treatment of overt hepatic encephalopathyJ Hepatol2014601S215S215
   Web of Science ®Google Scholar
• MiuHSalimAAfzalMSMalikKAminJButtAKComparison of Rifaximin and Lactulose With Lactulose Alone in the Treatment of Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis[J]Proceeding S.Z.P.G.M.I2014282115119
   Google Scholar
• CoursonAJonesGMTwillaJDTreatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient OutcomesJ Pharm Pract201629321221725586470
   PubMedGoogle Scholar
• KangSHLeeYBLeeJHRifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathyAliment Pharmacol Ther201746984585528836723
   PubMed Web of Science ®Google Scholar
• AhireKSonawaleAComparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic EncephalopathyJ Assoc Physicians India201765842
   PubMedGoogle Scholar
• HasanSDattaSBhattacherjeeSA Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy[J]J Assoc Phys India20186632
   PubMedGoogle Scholar
• TapperEBJiangZGPatwardhanVRRefining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathyMayo Clin Proc201590564665825865476
   PubMed Web of Science ®Google Scholar
• QureshiMOKhokharNShafqatFAmmonia levels and the severity of hepatic encephalopathyJ Coll Physicians Surg Pak201424316016324613109
   PubMed Web of Science ®Google Scholar
• PatelVCWhiteHStøySBajajJSShawcrossDLClinical science workshop: targeting the gut-liver-brain axisMetab Brain Dis20163161327133726446022
   PubMed Web of Science ®Google Scholar
• SharmaPSharmaBCSarinSKPredictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathyEur J Gastroenterol Hepatol201022552653120009938
   PubMed Web of Science ®Google Scholar
• TranahTHVijayGKRyanJMShawcrossDLSystemic inflammation and ammonia in hepatic encephalopathyMetab Brain Dis20132811523224356
   PubMed Web of Science ®Google Scholar
• GiannelliVDi GregorioVIebbaVMicrobiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosisWorld J Gastroenterol20142045167951681025492994
   PubMed Web of Science ®Google Scholar
• LuoMLiLLuCZCaoWKClinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysisEur J Gastroenterol Hepatol201123121250125721971378
   PubMed Web of Science ®Google Scholar
• YangJLeeHRLowKChatterjeeSPimentelMRifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBSDig Dis Sci200853116917417520365
   PubMed Web of Science ®Google Scholar
• GluudLLDamGBorreMLactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?Metab Brain Dis201328222122523275147
   PubMed Web of Science ®Google Scholar